Abstract
Attention deficit-hyperactivity disorder (ADHD) is a very common and heterogeneous childhood-onset psychiatric disorder, affecting between 3% and 5% of school age children worldwide. Although the neurobiology of ADHD is not completely understood, imbalances in both dopaminergic and noradrenergic systems have been implicated in the origin and persistence of core symptoms, which include inattention, hyperactivity, and impulsivity. The role of a genetic component in its etiology is strongly supported by genetic studies, and several investigations have suggested that the dopamine transporter gene (DAT1; SLC6A3 locus) may be a small-effect susceptibility gene for ADHD.
Stimulant medication has a well-documented efficacy in reducing ADHD symptoms. Methylphenidate, the most prescribed stimulant, seems to act mainly by inhibiting the dopamine transporter protein and dopamine reuptake. In fact, its effect is probably related to an increase in extracellular levels of dopamine, especially in brain regions enriched in this protein (i.e. striatum). It is also important to note that dopamine transporter densities seem to be particularly elevated in the brain of ADHD patients, decreasing after treatment with methylphenidate. Altogether, these observations suggest that the dopamine transporter does play a major role in ADHD.
Among the several polymorphisms already described in the SLC6A3 locus, a 40 bp variable number of tandem repeats (VNTR) polymorphism has been extensively investigated in association studies with ADHD. Although there are some negative results, the findings from these reports indicate the allele with ten copies of the 40 bp sequence (10-repeat allele) as the risk allele for ADHD. Some investigations have suggested that this polymorphism can be implicated in dopamine transporter gene expression in vitro and dopamine transporter density in vivo, even though it is located in a non-coding region of the SLC6A3 locus. Despite all these data, few studies have addressed the relationship between genetic markers (specifically the VNTR) at the SLC6A3 locus and response to methylphenidate in ADHD patients. A significant effect of the 40 bp VNTR on response to methylphenidate has been detected in most of these reports. However, the findings are inconsistent regarding both the allele (or genotype) involved and the direction of this influence (better or worse response). Thus, further investigations are required to determine if genetic variation due to the VNTR in the dopamine transporter gene is able to predict different levels of clinical response and palatability to methylphenidate in patients with ADHD, and how this information would be useful in clinical practice.
Similar content being viewed by others
References
Biederman J. Attention deficit hyperactivity disorder: a life span perspective. J Clin Psychiatry 1998; 59Suppl. 7: 4–16
Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716–22
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Pliszka SR. Comorbidity of attention deficit hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998; 59Suppl. 7: 50–8
Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40: 147–58
Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36: 1222–7
Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121: 65–94
Levy F, Swanson JM. Timing, space and ADHD: the dopamine theory revisited. Aust N Z J Psychiatry 2001; 35: 504–11
Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiat 1998; 39: 65–99
Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 448–55
Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264–72
Szobot C, Ketzer C, Cunha RD, et al. The acute effect of methylphenidate on brain perfusion in male children and adolescents with ADHD: a randomized clinical trial. Eur J Nuclear Med 2003; 30: 423–6
Quist JF, Kennedy JL. Genetics of childhood disorders: XXIII. ADHD: Pt 7. The serotonin system. J Am Acad Child Adolesc Psychiatry 2001; 40: 253–6
Rohde LA, Roman T, Szobot C, et al. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in ADHD. Synapse 2003; 48: 87–9
Thapar A, Holmes J, Poulton K, et al. Genetic basis of attention deficit and hyperactivity. Br J Psychiary 1999; 174: 105–11
Milberger S, Faraone SV, Biederman J, et al. New phenotype definition of attention deficit hyperactivity disorder in relatives for genetic analyses. Am J Med Genet (Neuropsychiatr Genet) 1996; 67: 369–77
Faraone SV, Biederman J. Neurobiology of attention deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951–8
Faraone SV, Doyle AE. The nature and heritability of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2001; 10: 299–316
Sprich S, Biederman J, Crawford MH, et al. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2000; 39: 1432–7
Smalley SL. Genetic influences in childhood-onset psychiatric disorders: autism and attention deficit hyperactivity disorder. Am J Hum Genet 1997; 60: 1276–82
Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 1991; 25: 277–83
Castellanos FX. Toward a pathophysiology of attention deficit hyperactivity disorder. Clin Pediatr 1997; 36: 381–93
Kirley A, Hawi Z, Daly G, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 2002; 27: 607–19
DiMaio S, Grizenko N, Joober R. Dopamine genes and attention deficit hyperactivity disorder: a review. J Psychiatry Neurosci 2003; 28: 27–38
Hawi Z, Dring M, Kirley A, et al. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT1B receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry 2002; 7: 718–25
Mill J, Curran S, Kent L, et al. Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am J Med Genet (Neuropsychiatr Genet) 2002; 11: 269–71
Roman T, Schmitz M, Polanczyk GV, et al. Is the α-2a adrenergic receptor gene (ADRA2A) associated with attention deficit hyperactivity disorder? Am J Med Genet (Neuropsychiatr Genet) 2003; 120B: 116–20
Todd RD, Lobos EA, Sun L-W, et al. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry 2003; 8: 103–8
Kent L, Doerry U, Hardy E, et al. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit/hyperactivity disorder (ADHD): analysis and pooled analysis. Mol Psychiatry 2002; 7: 908–12
Biederman J, Spencer T. Attention deficit hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46: 1234–42
Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–28
The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86
Szobot C, Ketzer C, Parente MA, et al. Acute effect of methylphenidate in Brazilian male children and adolescents with ADHD: a randomized clinical trial. J Attent Disorders. In press
Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127–52
Masellis M, Basile VS, Muglia P, et al. Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention deficit hyperactivity disorder. Behav Brain Res 2002; 130: 85–90
Volkow ND, Wang G-J, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: (RC21): 1–5
Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998; 3: 386–96
Volkow ND, Ding Y-S, Fowler JS, et al. Is methylphenidate like cocaine? Arch Gen Psychiatry 1995; 52: 456–63
Vaidya CJ, Austin G, Kirkorian G, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 1998; 95: 14494–9
Krause KH, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285: 107–10
Madras BK, Miller GM, Fischman AJ. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 2002; 130: 57–63
Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354: 2132–3
Dresel S, Krause J, Krause KH, et al. Attention deficit hyperactivity disorder: binding of [99mTc] TROD AT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000; 27: 1518–24
Cheon KA, Ryu YH, Kim YK, et al. Dopamine transporter density in the basal ganglia assessed with [(123)I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 2003; 30: 306–11
Giros B, el Mestikawy S, Godinot N, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992; 42: 383–90
Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104–6
Bannon MJ, Michelhaugh SK, Wang J, et al. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 2001; 11: 449–55
Sano A, Kondoh K, Kakimoto Y, et al. A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 1993; 91: 405–6
Min Kang A, Palmatier MA, Kidd KK. Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 1999; 46: 151–60
Mill J, Asherson P, Browes C, et al. Expression of the dopamine transporter gene is regulated by the 3′UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet (Neuropsychiatr Genet) 2002; 114: 975–9
Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet 1998; 43: 149–52
Miller GM, Madras BK. Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002; 7(1): 44–55
Michelhaugh SK, Fiskerstrand C, Lovejoy E, et al. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 2001; 79: 1033–8
Fuke S, Suo S, Takahashi N, et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001; 1: 152–6
Heinz A, Goldman D, Jones DW, et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133–9
Jacobsen LK, Staley JK, Zoghbi SS, et al. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 2000; 157: 1700–3
Martinez D, Gelernter J, Abi-Dargham A, et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001; 24: 553–60
Hawi Z, Lowe N, Kirley A, et al. Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci. Mol Psychiatry 2003; 8: 299–308
Miller GM, De La Garza II R, Novak MA, et al. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. Mol Psychiatry 2001; 6: 50–8
Muglia P, Jain U, Inkster B, et al. A quantitative trait locus analysis of the dopamine transporter gene in adults with ADHD. Neuropsychopharmacology 2002; 27: 655–62
Cook EH, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993–8
Maher BS, Marazita ML, Ferrell RE, et al. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr Genet 2002; 12: 207–15
Crowe RR. Candidate genes in psychiatry: an epidemiological perspective. Am J Med Genet 1993; 15: 74–7
Suarez BK, Hampe CL, Van Eerdewegh P. Problems of replicating linkage claims in psychiatry. In: Gershon ES, Cloninger CR, Barret JE, editors. Genetic approaches in mental disorders. Washington, DC: American Psychiatric Press, 1994: 23–46
Barr CL, Xu C, Kroft J, et al. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention deficit hyperactivity disorder. Biol Psychiatry 2001; 49: 333–9
Gill M, Daly G, Heron S, et al. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997; 2: 311–3
Waldman ID, Rowe DC, Abramowitz A, et al. Association and linkage of the dopamine transporter gene (DAT1) and attention deficit hyperactivity disorder in children. Am J Hum Genet 1998; 63: 1767–76
Daly G, Hawi Z, Fitzgerald M, et al. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 1999; 4: 192–6
Palmer CGS, Bailey JN, Ramsey C, et al. No evidence of linkage or linkage disequilibrium between DAT1 and attention deficit hyperactivity disorder in a large sample. Psychiatr Genet 1999; 9: 157–60
Holmes J, Payton A, Barret JH, et al. A family-based and case-control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol Psychiatry 2000; 5: 523–30
Swanson JM, Flodman P, Kennedy J, et al. Dopamine genes and ADHD. Neurosci Biobehav Rev 2000; 24: 21–5
Curran S, Mill J, Tahir E, et al. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry 2001; 6: 425–8
Roman T, Schmitz M, Polanczyk G, et al. Attention deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet (Neuropsychiatr Genet) 2001; 105: 471–8
Rowe DC, Stever C, Chase D, et al. Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. Mol Psychiatry 2001; 6: 429–33
Todd RD, Jong Y-JI, Lobos EA, et al. No association of the dopamine transporter gene 3′ polymorphism with ADHD subtypes in a population sample of twins. Am J Med Genet (Neuropsychiatr Genet) 2001; 105: 745–8
Payton A, Holmes J, Barret JH, et al. Susceptibility genes for a trait measure of attention deficit hyperactivity disorder: a pilot study in a non-clinical sample of twins. Psychiatry Res 2001; 105: 273–8
Smith KM, Daly M, Fischer M, et al. Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study. Am J Med Genet (Neuropsychiatr Genet) 2003; 119B: 77–85
Chen C-K, Chen S-L, Mill J, et al. The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol Psychiatry 2003; 8: 393–6
Rohde LA, Roman T, Hutz MH. Attention deficit hyperactivity disorder: current aspects on pharmacogenetics. Pharmacogenomics J 2003; 3: 11–3
Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38: 1474–7
Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 1985; 21: 809–43
Stein MA, Sarampote C, Waldman I, et al. Dopamine transporter genotype affects stimulants response according to parent ratings. The Scientific Proceedings of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 23–26; San Francisco
Roman T, Martins S, Szobot C, et al. Dopamine transporter gene and response to methylphenidate in ADHD. Pharmacogenetics 2002; 12: 497–9
Hamarman S. ADHD children with DRD4 7-repeat allele require higher stimulant doses. The Scientific Proceedings of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 23–26; San Francisco
Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet (Neuropsychiatr Genet) 2003; 121B: 50–4
Volkow N, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002; 43: 181–7
Tribut O, Lessard Y, Reymann J-M, et al. Pharmacogenetics. Med Sci Monit 2002; 8: RA152–63
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roman, T., Rohde, L.A. & Hutz, M.H. Polymorphisms of the Dopamine Transporter Gene. Am J Pharmacogenomics 4, 83–92 (2004). https://doi.org/10.2165/00129785-200404020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129785-200404020-00003